Drugs / Montelukast
last change 3 days ago re-read 2 minutes ago

Montelukast

also known as Montelukast sodium · singulair · MK0476 · MON · Brondilat · GW483100 · MK-476 · MKT-N2 · +8 more

Other / unclassified targets ACE2, CYP2C8, CYSLTR1 via inhibition

Developed for
asthma · allergic rhinitis · seasonal allergic rhinitis · exercise-induced bronchoconstriction · perennial allergic rhinitis · COVID-19 · rheumatoid arthritis · atopic eczema
+75 more · bronchiolitis · bronchopulmonary dysplasia · chronic asthma · status asthmaticus · type 2 diabetes mellitus · acute asthma · allergic respiratory disease · Alzheimer disease · bronchiolitis obliterans syndrome · cough variant asthma · eosinophilic esophagitis · lung disorder · metabolic dysfunction-associated steatohepatitis · otitis media with effusion · rhinitis · transplant-related bronchiolitis obliterans · acute bronchiolitis · atherosclerosis · brain neoplasm · childhood onset asthma · chronic graft versus host disease · chronic obstructive pulmonary disease · chronic rhinosinusitis · colorectal cancer · cryptogenic organizing pneumonia · dengue disease · diabetic kidney disease · dyspepsia · endometrial cancer · environmental induced asthma · eosinophilic gastroenteritis · erythema nodosum · idiopathic nephrotic syndrome · infectious disease with sepsis · kidney disorder · limb ischemia · lower respiratory tract disorder · Meniere disease · multiple sclerosis · nasal cavity polyp · neonatal sepsis · obstructive sleep apnea syndrome · osteoarthritis, knee · ovarian cancer · ovarian hyperstimulation syndrome · peripheral arterial disease · persian gulf syndrome · pneumonia · proteinuria · reactive airway disease · respiratory syncytial virus bronchiolitis · retinal disorder · sarcoma · severe acute respiratory syndrome · sickle cell disease · sinusitis · sleep apnea syndrome · ST-elevation myocardial infarction · transplant rejection · vascular disorder · viral respiratory tract infection · acne · acute coronary syndrome · acute myocardial infarction · bronchitis · chemotherapy-induced toxicity · chronic kidney disease · chronic periodontitis · conjunctivitis · coronary artery disorder · coronary atherosclerosis · obstructive lung disease · otitis media · Parkinson disease · post-COVID-19 disorder
Investigated by
Organon and Co · Merck Sharp & Dohme LLC · Bristol-Myers Squibb · GlaxoSmithKline · National Heart, Lung, and Blood Institute (NHLBI) · Vanderbilt University Medical Center
+147 more · Hanmi Pharmaceutical Company Limited · University of Colorado, Denver · Ajou University School of Medicine · Assaf-Harofeh Medical Center · Beijing Chao Yang Hospital · Children's Hospital Medical Center, Cincinnati · Children's Mercy Hospital Kansas City · Duke University · Hormozgan University of Medical Sciences · Indiana University · Medical College of Wisconsin · Milton S. Hershey Medical Center · National Cancer Institute (NCI) · National Center for Advancing Translational Sciences (NCATS) · Phramongkutklao College of Medicine and Hospital · Sadat City University · Susanna Naggie, MD · University of California, San Francisco · University of Massachusetts, Worcester · ViiV Healthcare · 1st Allergy & Clinical Research Center · Act For Chronic Diseases · Ain Shams University · Ambulatory Pediatric Association · American Academy of Pediatrics · American College of Clinical Pharmacy · American Lung Association Asthma Clinical Research Centers · Arkansas Children's Hospital Research Institute · Assiut University · AstraZeneca · Austin V Stone · Azienda Ospedaliera Universitaria Policlinico · Bahçeşehir University · Baylor College of Medicine · Beijing Tongren Hospital · Benha University · Bernstein, Jonathan A., M.D. · Biogen · Brigham and Women's Hospital · Brighton and Sussex University Hospitals NHS Trust · Bugra Kerget · Cantonal Hosptal, Baselland · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chinese Academy of Medical Sciences · Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) · Clinision · Corrie Fletcher · Creighton University · Cures Within Reach · Damanhour University · Direction Générale de l'Offre de Soins · East Carolina University · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Firestone Institute for Respiratory Health · First Affiliated Hospital, Sun Yat-Sen University · Gangnam Severance Hospital · Government Medical College, Bhavnagar · Guangzhou Institute of Respiratory Disease · H. Lundbeck A/S · Hal C Charles · Hallym University Medical Center · Hawaa Fertility Center · House Ear Institute · Hyundai Pharmaceutical Co., LTD. · Indira Gandhi Medical College, Shimla · Inje University · Institut Català de la Salut · IntelGenx Corp. · Isala · Istanbul Training and Research Hospital · JHSPH Center for Clinical Trials · Jagiellonian University · Janssen Research & Development, LLC · all 153 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (7) US (FDA) SINGULAIR 2000-03-03 – 2012-03-26 fda.gov
Approved US (FDA) SINGULAIR 1998-02-20 fda.gov

Trials 197 · started per year

today
US approved 1998
1
1
1
2
5
8
4
12
11
14
14
13
7
3
8
7
6
9
8
6
5
5
5
8
7
8
6
5
4
4
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 05 trials
Phase 0 NCT07409714 Jul 2026 → Feb 2030 expected type 2 diabetes mellitus University of Colorado, Denver Not yet recruiting No outcome recorded
Phase 0 NCT06887673 Mar 2025 → Mar 2026 overdue brain neoplasm, colorectal cancer, endometrial cancer, ovarian cancer +1 University of South Florida Not yet recruiting No outcome recorded
Phase 0 NCT04572256 Feb 2021 → Jun 2027 expected osteoarthritis, knee Austin V Stone Recruiting No outcome recorded
Phase 0 NCT04075110 Jul 2019 → Jun 2022 type 2 diabetes mellitus Sadat City University Completed No outcome recorded
Phase 0 NCT04077892 Jun → Sep 2016 allergic rhinitis Beijing Tongren Hospital Completed No outcome recorded
Phase 126 trials
Phase 1 NCT05992311 Aug 2025 → Apr 2028 expected persian gulf syndrome Baylor College of Medicine Recruiting No outcome recorded
Phase 1 NCT05852769 May → Aug 2023 Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT05607446 Sep 2022 → May 2023 allergic rhinitis Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Terminated No outcome recorded
Phase 1 NCT04425902 Dec 2020 → Mar 2021 HIV infectious disease ViiV Healthcare Completed No outcome recorded
Phase 1 NCT04474327 Jul 2020 → Feb 2021 neonatal sepsis Mansoura University Children Hospital Completed No outcome recorded
Phase 1 NCT04275115 Feb → Apr 2020 H. Lundbeck A/S Completed No outcome recorded
Phase 1 NCT04097951 Nov 2019 → Jan 2020 respiratory system disorder Hyundai Pharmaceutical Co., LTD. Unknown No outcome recorded
Phase 1 NCT03371849 Jul → Aug 2017 Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 1 NCT03131973 May → Nov 2017 rheumatoid arthritis Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT02762123 May → Aug 2016 rheumatoid arthritis Bristol-Myers Squibb Completed No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT07101640 Feb 2026 → Jun 2027 expected bronchopulmonary dysplasia Duke University Recruiting No outcome recorded
Phase 1/2 NCT05143502 Jan 2022 → Jan 2024 chronic rhinosinusitis Assiut University Unknown No outcome recorded
Phase 1/2 NCT04080947 Aug 2019 → Aug 2021 metabolic dysfunction-associated steatohepatitis Sadat City University Completed No outcome recorded
Phase 226 trials
Phase 2 NCT03277170 Sep 2025 → Aug 2028 acute asthma, childhood onset asthma, status asthmaticus Vanderbilt University Medical Center Withdrawn No outcome recorded
Phase 2 NCT05819541 Oct 2023 → Mar 2026 status asthmaticus Vanderbilt University Medical Center Completed No outcome recorded
Phase 2 NCT05663866 May 2023 → Mar 2024 overdue non-small cell lung carcinoma Janssen Research & Development, LLC Active not recruiting No outcome recorded
Phase 2 NCT05447520 Dec 2021 → Dec 2022 rheumatoid arthritis Noha Mansour Completed No outcome recorded
Phase 2 NCT04718285 May 2021 → May 2022 COVID-19 Bahçeşehir University Unknown No outcome recorded
Phase 2 NCT04198623 Mar 2020 → Jul 2024 University of California, San Francisco Completed No outcome recorded
Phase 2 NCT03991988 Sep 2019 → Nov 2022 Alzheimer disease Emory University Completed No outcome recorded
Phase 2 NCT04374981 Jul → Nov 2019 Damanhour University Completed No outcome recorded
Phase 2 NCT03794037 Dec 2018 → Dec 2023 ovarian hyperstimulation syndrome Benha University Suspended No outcome recorded
Phase 2 NCT03402503 Nov 2018 → Mar 2024 Alzheimer disease IntelGenx Corp. Completed No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT06747130 Jan 2025 → Jan 2027 expected dengue disease Phramongkutklao College of Medicine and Hospital Recruiting No outcome recorded
Phase 2/3 NCT04389411 Nov 2022 → Jan 2023 COVID-19 McGill University Unknown No outcome recorded
Phase 2/3 NCT05293132 Feb 2022 → Jun 2023 infectious disease with sepsis Ain Shams University Completed No outcome recorded
Phase 2/3 NCT04673422 Jan 2021 → Jun 2023 dengue shock syndrome Phramongkutklao College of Medicine and Hospital Completed No outcome recorded
Phase 2/3 NCT00115297 Sep 2004 → Oct 2016 asthma, lung disorder University of Massachusetts, Worcester Completed No outcome recorded
Phase 357 trials
Phase 3 NCT07320625 Feb 2026 → Feb 2027 expected ST-elevation myocardial infarction Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 3 NCT05894577 Jan → Jul 2023 COVID-19 Susanna Naggie, MD Completed No outcome recorded
Phase 3 NCT05362474 Jul 2022 → Jun 2023 diabetic kidney disease University of Colorado, Denver Terminated No outcome recorded
Phase 3 NCT04695704 Aug 2021 → Jul 2023 COVID-19, severe acute respiratory syndrome Jordi Gol Institute for Primary Care Research Terminated No outcome recorded
Phase 3 NCT04885530 Jun 2021 → Apr 2024 COVID-19 Susanna Naggie, MD Completed No outcome recorded
Phase 3 NCT04277702 May 2020 → Oct 2023 atherosclerosis, limb ischemia, peripheral arterial disease Jagiellonian University Unknown No outcome recorded
Phase 3 NCT03545997 Nov 2019 → Mar 2020 obstructive sleep apnea syndrome University Hospital, Grenoble Terminated No outcome recorded
Phase 3 NCT04324918 Oct 2018 → Jun 2019 perennial allergic rhinitis Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 3 NCT02793375 Aug 2018 → Nov 2024 Children's Hospital Medical Center, Cincinnati Completed No outcome recorded
Phase 3 NCT02541760 Apr 2014 → Mar 2015 otitis media with effusion Hormozgan University of Medical Sciences Completed No outcome recorded
Phase 453 trials
Phase 4 NCT07685886 Sep 2026 → Jun 2031 expected kidney disorder, retinal disorder, type 2 diabetes mellitus, vascular disorder University of Colorado, Denver Not yet recruiting No outcome recorded
Phase 4 NCT05498116 Jan 2023 → Feb 2027 expected proteinuria University of Colorado, Denver Recruiting No outcome recorded
Phase 4 NCT05651750 Nov 2022 → May 2023 Assaf-Harofeh Medical Center Unknown No outcome recorded
Phase 4 NCT05094596 Oct → Dec 2021 pneumonia Bugra Kerget Unknown No outcome recorded
Phase 4 NCT04815187 Jun 2021 → Sep 2025 overdue Meniere disease, allergic rhinitis House Ear Institute Active not recruiting No outcome recorded
Phase 4 NCT04957927 Dec 2020 → Sep 2021 allergic rhinitis Usama Azhar Unknown No outcome recorded
Phase 4 NCT04537780 Aug 2019 → Aug 2020 metabolic dysfunction-associated steatohepatitis Tanta University Completed No outcome recorded
Phase 4 NCT03380975 Aug 2018 → Mar 2019 allergic respiratory disease Clinision Completed No outcome recorded
Phase 4 NCT03269318 Jul 2017 → Aug 2019 asthma Brighton and Sussex University Hospitals NHS Trust Terminated No outcome recorded
Phase 4 NCT03096327 May → Dec 2017 asthma PharmEvo Pvt Ltd Completed No outcome recorded
Phase not applicable22 trials
NCT04322422 Jun 2020 → Jul 2022 anxiety, asthma, depressive disorder, eosinophil disorder +1 Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
NCT04818723 Feb 2019 → May 2020 idiopathic nephrotic syndrome Nishtar Medical University Completed No outcome recorded
NCT03039101 Sep 2017 → Jul 2018 allergic rhinitis Mitchell Grayson Completed No outcome recorded
NCT02758873 Feb 2016 → Jul 2019 asthma University of Sussex Completed No outcome recorded
NCT01967498 Nov 2013 → Dec 2015 conductive hearing loss disorder, otitis media with effusion Tel-Aviv Sourasky Medical Center Unknown No outcome recorded
NCT01770899 Jan → Dec 2013 status asthmaticus Corrie Fletcher Unknown No outcome recorded
NCT01841164 May 2012 → Jun 2014 asthma Karolinska University Hospital Unknown No outcome recorded
NCT01458418 Dec 2011 → Feb 2015 eosinophilic esophagitis Children's Mercy Hospital Kansas City Terminated No outcome recorded
NCT01329939 Apr 2011 → Sep 2014 asthma, obesity disorder Northwell Health Completed No outcome recorded
NCT01370187 Jul 2010 → Apr 2011 acute bronchiolitis, cough variant asthma Hormozgan University of Medical Sciences Completed No outcome recorded
Also used as a comparator or background therapy in 113 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05381207 Comparator Oct 2022 → Oct 2024 allergic rhinitis Assiut University Unknown No outcome recorded
Phase 14 trials
Phase 1 NCT01998971 Background Feb 2014 → Jan 2019 plasma cell myeloma Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT01491503 Comparator Nov 2011 → Jan 2012 Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase 1 NCT00856687 Comparator Apr → Dec 2009 asthma Pfizer Completed No outcome recorded
Phase 1 NCT00664937 Comparator May 2007 → Oct 2008 exercise-induced bronchoconstriction Organon and Co Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT04294459 Background Jun 2020 → May 2022 immune system disorder Sanofi Terminated No outcome recorded
Phase 227 trials
Phase 2 NCT07537868 Comparator Apr 2026 → May 2027 expected acute myocardial infarction October 6 University Recruiting No outcome recorded
Phase 2 NCT06356571 Background Mar 2025 → Jan 2027 expected plasma cell myeloma Sanofi Recruiting No outcome recorded
Phase 2 NCT05922761 Background May 2024 → Jun 2027 expected chronic graft versus host disease, transplant-related bronchiolitis obliterans Dana-Farber Cancer Institute Recruiting No outcome recorded
Phase 2 NCT05896228 Background Feb 2024 → Mar 2029 expected plasma cell myeloma Benjamin T Diamond, MD Recruiting No outcome recorded
Phase 2 NCT05807048 Background Jun 2023 → Nov 2025 lung cancer NYU Langone Health Completed No outcome recorded
Phase 2/36 trials
Phase 2/3 NCT06113640 Comparator Nov 2023 → Nov 2026 expected Parkinson disease Mostafa Bahaa Recruiting No outcome recorded
Phase 2/3 NCT04351698 Comparator Oct 2023 → Sep 2024 obstructive sleep apnea syndrome, sickle cell disease Great Ormond Street Hospital for Children NHS Foundation Trust Unknown No outcome recorded
Phase 2/3 NCT01951898 Comparator Jun 2012 → Dec 2013 asthma Kurume University Unknown No outcome recorded
Phase 2/3 NCT00491790 Comparator Dec 2006 → Jan 2010 status asthmaticus Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Unknown No outcome recorded
Phase 2/3 NCT00494572 Comparator Dec 2006 → Jan 2010 status asthmaticus Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Unknown No outcome recorded
Phase 319 trials
Phase 3 NCT06429475 Comparator Jun 2024 → Dec 2028 expected asthma University of KwaZulu Recruiting No outcome recorded
Phase 3 NCT06340984 Comparator Jun → Nov 2024 acne South Valley University Unknown No outcome recorded
Phase 3 NCT05405166 Background Jun 2022 → Nov 2024 overdue plasma cell myeloma Sanofi Active not recruiting No outcome recorded
Phase 3 NCT05325489 Background Apr 2022 → Nov 2023 Second Xiangya Hospital of Central South University Unknown No outcome recorded
Phase 3 NCT04270409 Background Jun 2020 → Oct 2030 expected plasma cell myeloma Sanofi Active not recruiting No outcome recorded
Phase 439 trials
Phase 4 NCT07532993 Comparator Sep 2026 → Feb 2027 expected allergic rhinitis Liaquat National Hospital & Medical College Not yet recruiting No outcome recorded
Phase 4 NCT07101445 Background Sep 2025 → Dec 2026 expected plasma cell myeloma Emory University Recruiting No outcome recorded
Phase 4 NCT07533565 Comparator Jul 2024 → Jul 2025 asthma, cirrhosis of liver Kafrelsheikh University Completed No outcome recorded
Phase 4 NCT06019728 Background Nov 2023 → Oct 2024 Fabry disease Sanofi Completed No outcome recorded
Phase 4 NCT04762472 Comparator Sep 2023 → Dec 2024 coronary atherosclerosis Chinese University of Hong Kong Unknown No outcome recorded
Phase not applicable16 trials
NCT06597682 Background Mar 2025 → Jul 2027 expected long COVID-19 Huashan Hospital Not yet recruiting No outcome recorded
NCT05959889 Comparator Mar 2023 → Nov 2024 breast cancer, chemotherapy-induced toxicity Damanhour University Completed No outcome recorded
NCT05447039 Comparator Sep → Nov 2020 post-COVID-19 disorder Assiut University Completed No outcome recorded
NCT04621513 Background Jul 2020 → Dec 2021 obstructive sleep apnea syndrome China Medical University Hospital Unknown No outcome recorded
NCT04561687 Comparator Jan 2020 → Sep 2021 allergic rhinitis Shiraz University of Medical Sciences Unknown No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2009-08-19 Teva Branded Pharmaceutical Products R&D, Inc. Teva Provides Update On Generic Singulair® Litigation tevapharm.com

Evidence & citations 21 cited values

Every value below carries the sentence it was read from. 314 sources stand behind the page.

FieldValueCited text
Known as montelukast “Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin)...” NCT02578277
299

“Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg” NCT02045966

“The participants will receive tretment of HCP1102(combination of Montelukast + Levocetrizine), orally, once daily for 4weeks.” NCT04324918

Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial.” PMID 28894551 Jul 2017

Montelukast (Singulair ) is a selective leukotriene-receptor antagonist that inhibits the cysteinyl leukotriene 1 receptor.” NCT00551382

“Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc” NCT06429475

“Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)” NCT04275115

“receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks” NCT04077892

“a tablet treatment for asthma called Singulair (montelukast)” NCT00273013

Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD” NCT04621513

“oral montelukast sodium chewable tablets 4mg QD” NCT05325489

Montelukast 10mg PO prior to DARZALEX FASPRO®.” NCT05807048

Montelukast and Bepotastine Combination” NCT04097951

montelukast(4mg od for 3 months)” NCT04527016

Montelukast (ML)” NCT01624974

MontelukastNCT02758873

NCT00947453

NCT02321748

NCT01615874

NCT00295022

NCT02104674

NCT00359073

NCT03039101

NCT03131973

NCT01621386

NCT00543686

NCT04270409

NCT04613180

NCT00739297

NCT04425902

NCT00380705

NCT00398151

NCT00471809

NCT00974571

NCT02565212

NCT01967498

NCT00394355

NCT00299910

NCT01804400

NCT00755794

NCT00140881

NCT01211509

NCT01016847

NCT00375232

NCT00756418

NCT01224964

NCT04294641

NCT01673620

NCT00328718

NCT07101445

NCT00140946

NCT00655616

NCT01103349

NCT02559388

NCT04294459

NCT00656058

NCT00462592

NCT01370187

NCT02494466

NCT01147744

NCT00491790

NCT01730027

NCT07101640

NCT00934713

NCT00453765

NCT00511316

NCT00115297

NCT01857063

NCT00770900

NCT05894577

NCT01717625

NCT04351698

NCT00092989

NCT00492102

NCT01248975

NCT00911547

NCT04474327

NCT06747130

NCT00296491

NCT01156792

NCT00092885

NCT03545997

NCT07409714

NCT00245570

NCT04572256

NCT02227173

NCT05381207

NCT01640535

NCT04695704

NCT00968149

NCT00968201

NCT02322671

NCT05959889

NCT00379808

NCT00943683

NCT03380975

NCT00116324

NCT01432080

NCT05362474

NCT00394160

NCT00045955

NCT01725360

NCT01998971

NCT00863317

NCT02108886

NCT00666679

NCT00406861

NCT00394069

NCT02483975

NCT00319995

NCT01011452

NCT00162864

NCT00771160

NCT02110654

NCT01055041

NCT07685886

NCT00943397

NCT01696214

NCT00814281

NCT00636207

NCT01841164

NCT00296530

NCT01754220

NCT00189462

NCT07532993

NCT04322422

NCT01266772

NCT05498116

NCT00319488

NCT02551536

NCT02014532

NCT07533565

NCT00189475

NCT04268498

NCT00490243

NCT00351364

NCT01960413

NCT00284856

NCT05852769

NCT01951898

NCT01304901

NCT02479074

NCT00875082

NCT00395304

NCT02456844

NCT01089647

NCT01142505

NCT00783601

NCT00960141

NCT02762123

NCT00565955

NCT01852812

NCT00461032

NCT05405166

NCT00406094

NCT05663866

NCT00229970

NCT03794037

NCT01404013

NCT02655562

NCT06356571

NCT01414868

NCT05143502

NCT02635334

NCT00117338

NCT02761252

NCT00545324

NCT00446186

NCT01007721

NCT00963599

NCT01147510

NCT04818723

NCT00963469

NCT05992311

NCT05651750

NCT04815187

NCT01606306

NCT01656395

NCT01702701

NCT00712335

NCT00487773

NCT01458418

NCT03096327

NCT01770899

NCT01491503

NCT03402503

NCT00721240

NCT06597682

NCT00090142

NCT00289874

NCT02410278

NCT03269318

NCT05819541

NCT05293132

NCT04673422

NCT00935415

NCT00979901

NCT04389411

NCT03277170

NCT00213252

NCT00664937

NCT01279668

NCT00148408

NCT00196547

NCT00148603

NCT04374981

NCT00446056

NCT00380484

NCT02303600

NCT00157937

NCT02720081

NCT00488176

NCT00504946

NCT00524693

NCT00092144

NCT00092131

NCT00903357

NCT00127166

NCT00092118

NCT01526161

NCT01618929

NCT00156819

NCT00856687

NCT01027806

NCT00557284

NCT00119015

NCT00912171

NCT03372473

NCT01061333

NCT04762472

NCT00445107

NCT00092105

NCT07537868

NCT03770923

NCT01241422

NCT03371849

NCT00353184

NCT07320625

NCT04537780

NCT00559546

NCT06113640

NCT04718285

NCT04198623

NCT06019728

NCT00092092

NCT00127647

NCT04075110

NCT00832455

NCT02758873

NCT00972738

NCT00489346

NCT01765192

NCT02352545

NCT03369119

NCT00494572

NCT04885530

NCT00337675

NCT03991988

NCT01551147

NCT01086527

NCT06887673

NCT02029313

NCT01536041

NCT00534976

NCT00395408

NCT00641472

NCT00442559

NCT00424580

NCT00590772

NCT00076973

NCT04957927

NCT00442338

NCT00423995

NCT04561687

NCT02534467

NCT02793375

NCT01581710

NCT00273689

NCT01121016

NCT05447520

NCT02889809

NCT06340984

NCT00775697

NCT00599534

NCT05896228

NCT00675285

NCT01329939

NCT05447039

NCT05704049

NCT01437735

NCT02401256

NCT04080947

NCT00913328

NCT00700661

NCT05094596

NCT00961155

NCT04277702

NCT00311051

NCT05922761

NCT00936624

Known as Brondilat ChEMBL registry synonym — accepted as the source's own label CHEMBL787
Known as GW483100 “It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.” NCT02322671
Known as MK-476 ChEMBL registry synonym — accepted as the source's own label CHEMBL787
Known as MK0476 “The Safety and Effectiveness of MK0476 (Montelukast) in Patients With Chronic Asthma (0476-388)” NCT00739297
15

MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks” NCT00545324

MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00380705

MK0476, montelukast sodium / Duration of Treatment: 12 Weeks” NCT00398151

MK0476, Montelukast Sodium /Duration of Treatment : 14 Days” NCT00394160

MK0476, montelukast sodium / Duration of Treatment: 2 Weeks” NCT00446186

MK0476, montelukast sodium / Duration of Treatment: 4 weeks” NCT00092144

MK0476, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00445107

MK0476, montelukast sodium / Duration of Treatment: 4 Weeks” NCT00446056

MK0476; montelukast sodium/Duration of Treatment: 16 weeks” NCT00157937

MK0476, montelukast sodium / Duration of Treatment: 1 Year” NCT00489346

“MK-0476, montelukast sodium” NCT00394069

MK0476; montelukast sodium” NCT00140881

MK0476, montelukast sodium” NCT00395408

MK0476, montelukast sodium” NCT00092105

MK0476, montelukast sodium” NCT00092885

Known as MKT-N2 MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma” NCT02029313
Known as MLKT “10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.” NCT00295022
Known as MNT “receiving budesonide (BD, 256ug) plus montelukast (MNT, 10 mg) or BD alone (256ug) for 2 weeks” NCT04077892
Known as MON “Limited information exists comparing fluticasone propionate/salmeterol combination (FSC) versus montelukast (MON) in patients with coexistent asthma and allergic rhinitis.” PMID 20167147 Jan 2010
2

“Investigating the efficacy and safety of rupatadine (RUP) versus montelukast (MON) as adjuvant therapy for patients with rheumatoid arthritis (RA).” PMID 34218304 Jul 2021

montelukast (MON)” NCT00296491

Known as Montelukast (as sodium) ChEMBL registry synonym — accepted as the source's own label CHEMBL787
Known as montelukast (Singulair) montelukast (Singulair)NCT00462592
Known as Montelukast monosodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL787
Known as Montelukast Oral Tablet “Drug: Montelukast Oral TabletNCT05381207
Known as Montelukast sodium “A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in...” NCT00284856
47

“The purpose of this study is to evaluate the effectiveness of adding Montelukast Sodium (singulair®) 10 mg per day to inhaled corticosteroids in adult subjects with uncontrolled asthma.” NCT00755794

“A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma” NCT00832455

Montelukast Sodium, used in asthma treatment, is a cysteinyl leukotriene Type 1 antagonist which reduces leukotriene C4, leukotriene D4 and leukotriene E4 synthesis.” NCT02494466

Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults.” PMID 28639856 Jun 2017

“Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .” NCT02352545

“Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)” NCT00656058

Montelukast sodium (Singulair) will be given at a dose according to body weight.” NCT04474327

“MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks” NCT00545324

“MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma” NCT02029313

“MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00380705

“MK0476, montelukast sodium / Duration of Treatment: 12 Weeks” NCT00398151

montelukast sodium (Singulair), for the management of asthma” NCT00162864

“MK0476, montelukast sodium / Duration of Treatment: 2 Weeks” NCT00446186

“MK0476, montelukast sodium / Duration of Treatment: 4 weeks” NCT00092144

“MK0476, montelukast sodium / Duration of Treatment: 4 Weeks” NCT00446056

“MK0476, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00445107

“MK0476, Montelukast Sodium /Duration of Treatment : 14 Days” NCT00394160

“MK0476; montelukast sodium/Duration of Treatment: 16 weeks” NCT00157937

“MK0476, montelukast sodium / Duration of Treatment: 1 Year” NCT00489346

“Singulair: Montelukast sodium (leukotriene modulator)” NCT01424124

“Leukotriene Receptor Antagonist (Montelukast Sodium)” NCT00319488

Montelukast sodium is a white to off-white powder.” NCT04885530

“oral montelukast sodium chewable tablets 4mg QD” NCT05325489

Montelukast sodium 5 mg chewable tablets” NCT00092092

“MK-0476, montelukast sodiumNCT00394069

“MK0476, montelukast sodiumNCT00395408

“MK0476, montelukast sodiumNCT00092105

“MK0476, montelukast sodiumNCT00092885

“MK0476; montelukast sodiumNCT00140881

“Drug: montelukast sodiumNCT00770900

“Drug: montelukast sodiumNCT00911547

“Drug: Montelukast SodiumNCT00351364

“Drug: montelukast sodiumNCT00289874

“Drug: montelukast sodiumNCT00863317

“Drug: montelukast sodiumNCT00963469

“Drug: montelukast sodiumNCT00092989

“Drug: montelukast sodiumNCT00487773

“Drug: montelukast sodiumNCT00771160

“Drug: montelukast sodiumNCT00442338

“Drug: montelukast sodiumNCT00972738

“Drug: montelukast sodiumNCT00974571

“Drug: montelukast sodiumNCT00337675

Montelukast SodiumNCT00636207

NCT01307462

NCT05607446

NCT00545844

NCT00540839

Known as NSC-759107 ChEMBL registry synonym — accepted as the source's own label CHEMBL787
Known as singulair “A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic...” NCT00557284
19

“A 12 Week Multicenter, Open-label, Observational Study to Evaluate the Effectiveness of Montelukast Sodium (Singulair®), 4 or 5 mg/Day in Pediatric Subjects With Uncontrolled Asthma” NCT00832455

“Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)” NCT00395304

“determining how intervention with montelukast (singulair) affects symptoms and the rate of recurrent wheezing.” NCT00115297

“Montelukast (Singulair) is a drug that has been used for many years to treat asthma.” NCT00656058

“MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks” NCT00545324

“MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma” NCT02029313

“MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks” NCT00380705

“montelukast sodium (Singulair), for the management of asthma” NCT00162864

“At the remission stage: Singulair, once daily for 3 months.” NCT02341573

Singulair: Montelukast sodium (leukotriene modulator)” NCT01424124

“montelukast (singulair 10mg, daily)” NCT02110654

“Montelukast (Singulair®)” NCT01551147

“montelukast (Singulair)” NCT01536041

“Montelukast/ SingulairNCT00511316

NCT00421018

NCT00252863

NCT01651481

NCT00273013

NCT00385463

Known as singular ClinicalTrials.gov intervention name — accepted as the source's own label NCT00699062
Action Inhibit “Oral leukotriene receptor antagonists (eg montelukast)” NCT00045955
Modality Other / unclassified “leukotriene receptor antagonist (montelukast)” NCT00156819
Route Oral Oral leukotriene receptor antagonists (eg montelukast)” NCT00045955
Target CYP2C8 “montelukast is an powerful CYP2C8 inhibitor” NCT00453765